[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354588-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354588-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","supporting-adherence-to-adjuvant-cdk46-inhibitors-in-women-with-early-breast-cancer-sweet-plus-protocol-for-a-multicentre-uk-study-using-qualitative-and-co-development-methods","Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS) - protocol for a multicentre UK study using qualitative and co-development methods","","Breast cancer is the most common cancer in UK women, and daily oral adjuvant endocrine therapy for early-stage ER+ disease reduces recurrence risk. CDK4/6 inhibitors have been approved alongside endocrine therapy, yet trial evidence suggests adherence challenges. The SWEET-PLUS study explores women’s experiences, adherence support needs, and co-develops an intervention using evidence-based, theory-informed, patient-centred co-development with professionals and users.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/supporting-adherence-to-adjuvant-cdk46-inhibitors-in-women-with-early-breast-cancer-sweet-plus-protocol-for-a-multicentre-uk-study-using-qualitative-and-co-development-methods/354588/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/supporting-adherence-to-adjuvant-cdk46-inhibitors-in-women-with-early-breast-cancer-sweet-plus-protocol-for-a-multicentre-uk-study-using-qualitative-and-co-development-methods/354588.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the SWEET-PLUS study address?","Question",{"text":63,"@type":64},"The study addresses adherence challenges for women prescribed CDK4/6 inhibitors alongside endocrine therapy for early ER+ breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the SWEET-PLUS study design support intervention co-development?",{"text":68,"@type":64},"It uses three phases: interviews/focus groups with women, interviews/focus groups with healthcare professionals, then workshops and user testing interviews to co-develop an adherence support module.",{"name":70,"@type":61,"acceptedAnswer":71},"What analytical methods will be used for study findings?",{"text":72,"@type":64},"Phases I and II will use framework approach-based thematic analysis, while phase III will use content analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354588,1790457295,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Open access Protocol  \n Supporting adherence to adjuvant  \nCDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS): protocol for a multicentre UK study using qualitative and co  \ndevelopment methods  \nPearlin Teow  ,1 Lucy McGeagh  ,2 Henry Cain,3 Adam Todd  ,4 Farah Rehman,5 Jo Brett  ,2 Nicky Levitt,6 Mark Turner,7  \nSarah-Jane F Stewart  ,8 Emma Hunt,6 Hazeline Terrado,6 Eila Watson  ,2 Linda Sharp  1  \nTo cite: Teow P, McGeagh L, Cain H, et al. Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS): protocol fora multicentre UK study using qualitative and co-development methods. BMJ Open 2026;16:e119558 . doi:10 . 1136/ bmjopen-2026-119558  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2026-119558](bmjopen-2026-119558)) .  \nEW and LS are joint senior authors.  \nReceived 12 March 2026 Accepted 10 July 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. For numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Linda Sharp;  \n[Linda.Sharp@newcastle.ac.uk](Linda.Sharp@newcastle.ac.uk)  \nABSTRACT  \nIntroduction Breast cancer is the most common cancer in women in the UK. For women who have early-stage oestrogen-receptor positive (ER+ve) disease, daily oral adjuvant endocrine therapy reduces risk of recurrence. Recently, CDK4/6 inhibitors, a form of biological therapy, have been approved for use alongside endocrine therapy. However, trial data suggest there may be challenges with adherence to CDK4/6 inhibitors. This study aims to explore the experiences of adherence and support needs of women who have been prescribed CDK4/6 inhibitors for early ER+ve breast cancer. It will also co-develop an intervention to support women with adherence to these drugs alongside endocrine therapy through an evidencebased, theory-informed and patient-centred approach. Methods and analysis The SWEET-PLUS study has three phases. Phase I uses semi-structured interviews or focus groups to explore the experiences of women with early breast cancer who have been prescribed CDK4/6 inhibitors. It will also explore their support needs and experiences of adherence. Phase II involves interviews or focus groups with healthcare professionals who support CDK4/6 inhibitor prescription and associated care to understand the existing support and unmet needs. Phase I and II findings will inform phase III, which comprises workshops and user testing interviews to co-develop an intervention to support women with adherence to CDK4/6 inhibitors alongside endocrine therapy. This will be delivered as an additional module prototype designed for future integration into the existing HT&Me intervention, which supports women with adherence to endocrine therapy.  \nData from phases I and II will be analysed using a framework approach-based thematic analysis. Phase III data will be analysed through content analysis.  \nEthics and dissemination SWEET-PLUS received ethical approval from the National Health Services (NHS) Health Research Authority (Cambridge East Research Ethics Committee (25/EE/0220)) . Research findings will  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ Usage of a theory-informed framework that emphasises a no-blame approach towards medication adherence will enable comprehensive identification of the support needs of women on CDK4/6 inhibitors for early breast cancer.  \n⇒ Recruitment through National Health Service sites and supplementary avenues such as social media, charities and support groups will create opportunities to engage with harder to reach populations, including those who have poorer breast cancer outcomes.  \n⇒ Continual patient and public involvement throughout each phase will ensure that the study and the proposed intervention remain patie","cbCairqHdagSgwFk","https://ap.wps.com/l/cbCairqHdagSgwFk","pdf",1550231,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Ethics and dissemination\n# Strengths and limitations of this study\n# Introduction","[{\"question\":\"What problem does the SWEET-PLUS study address?\",\"answer\":\"The study addresses adherence challenges for women prescribed CDK4/6 inhibitors alongside endocrine therapy for early ER+ breast cancer.\"},{\"question\":\"How does the SWEET-PLUS study design support intervention co-development?\",\"answer\":\"It uses three phases: interviews/focus groups with women, interviews/focus groups with healthcare professionals, then workshops and user testing interviews to co-develop an adherence support module.\"},{\"question\":\"What analytical methods will be used for study findings?\",\"answer\":\"Phases I and II will use framework approach-based thematic analysis, while phase III will use content analysis.\"}]","Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS) - protocol for a multicentre UK study using qualitative and co-development methods | PDF",1790112351,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f46d394d171d21ea21a5b287fd939928.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af7c8146b81912b395f58fdc845a1e7e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7041925c39df3f188622005badbb078.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae3839ebd8994745a0b67523d3647640.webp",980,1306]